Abstract 1593
Background
The phase III WJOG4407G study showed non-inferiority of FOLFIRI plus bevacizumab to mFOLFOX6 plus bevacizumab in progression-free survival, as the first-line chemotherapy for patients with metastatic colorectal cancer. The aim of this study was to evaluate the predictive and prognostic value of morphologic response to first-line chemotherapy containing bevacizumab in patients with CLM.
Methods
This study is a post hoc analysis of patients from the WJOG4407G study. Morphologic response was assessed with the comparison of baseline and week 8 contrast-enhanced CT images. Three blinded radiologists evaluated CT images and classified as optimal, incomplete or none response according to the morphologic criteria. RECIST response, early tumor shrinkage (ETS) and depth of response (DpR) were also evaluated. The Cox proportional hazards model was used to investigate the association between radiological variables and progression-free survival (PFS) and overall survival (OS).
Results
Of 395 patients who were eligible for efficacy analysis in the WJOG4407G study, 70 patients had liver-limited disease. Enhanced CT images of 57 of these patients from 22 participating centers were collected. Two patients were excluded from this analysis because their post-chemotherapy metastases were too small. Optimal morphologic response was identified in 19 of 55 patients (34.5%). The median PFS was 10.7 months for patients with optimal response and 10.1 months in those with incomplete/no response (log-rank p = 0.96). The median OS was 26.2 and 35.5 months, respectively (log-rank p = 0.062). According to univariate analysis, morphologic response was not associated with PFS or OS, whereas RECIST response was significantly associated with both PFS and OS, with ETS and DpR being associated with significantly longer PFS.
Conclusions
Morphologic response might be neither predictive nor prognostic factor in patients with CLM undergoing chemotherapy containing bevacizumab, whereas RECIST response was significantly associated with both PFS and OS.
Clinical trial identification
UMIN000022171.
Legal entity responsible for the study
West Japan Oncology Group.
Funding
West Japan Oncology Group.
Editorial Acknowledgement
Disclosure
A. Hosokawa: Honoraria: Taiho, Chugai, Takeda, Ono, Novartis, Eisai, Eli Lilly; Research funding: Taiho, Chugai, Ono, Eisai, Yakult. K. Yamazaki: Speakers’ bureau: Chugai, Takeda, Taiho, Yakult, Merck Serono, Eli Lilly, Sanofi, Bayer E. Baba: Speakers’ bureau: Chugai, Eli Lilly; Research funding: Ono, Chugai, Eli Lilly, Takeda, Taiho, Merck Serono. K. Shinozaki: Honoraria: Chugai, Takeda, Mochida, Merck Serono, Taiho, Yakult, Astellas, Novartis, Eisai, Eli Lilly, Shionogi, Kyowa Hakko Kirin, Asahi Kasei, MSD. S. Morita: Honoraria: Chugai Pharma, Daiichi Sankyo. K. Muro: Honoraria: Chugai, Taiho, Bayer, Ono, Eli Lilly, Takeda; Research funding: Ono, MSD, Daiichi Sankyo, Kyowa Hakko Kirin, Gilead Sciences, Shionogi. All other authors have declared no conflicts of interest.
Resources from the same session
1159 - Molecular characterization and search for founding effects in Canarian families with Hereditary Breast and Ovarian Cancer Syndrome
Presenter: Elisenda Llabres Valenti
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3725 - Effect of the polymorphism rs2066844 of the NOD2 gene on colon cancer incidence in a high cardiovascular risk population. Modulation by gender
Presenter: Judith Begona Ramirez Sabio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3708 - Effect of the polymorphisms rs1476413, rs1801131, rs4846052 and rs6541003 of the MTHFR gene on prostate cancer in a high cardiovascular risk population
Presenter: Judith Begona Ramirez Sabio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5057 - Association of a genetic variant in cyclin-dependent kinase Inhibitor 2A gene with the increased risk of breast cancer
Presenter: Soodabeh Shahid Sales
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5970 - Investigating the role of HAT protein TIP60 in regulating functional dynamics of nuclear receptor PXR
Presenter: KARISHMA BAKSHI
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1360 - The role of downregulated SIRT3 expression in patients with hepatocellular carcinoma
Presenter: Hanhee Jo
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1634 - Prediction and Intervention of Colorectal Cancer Risk with Artificial Intelligent System
Presenter: Yang Ge
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4921 - Measuring the Efficiency of Cancer Care in Europe
Presenter: Rikard Althin
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1235 - Circulating cell-free DNA isolated from plasma of mesenteric veins predicts prognosis in stage II colorectal cancer patients
Presenter: Chih-Yung Yang
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5169 - _lonality of uterine carcinosarcoma as a factor of clinical prognosis.
Presenter: Natalia Levitskaya
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract